• Explore /
  • Poster
  • / A sequential therapy with sorafenib followed by regorafenib against single-line atezolizumab and bevacizumab in advanced hepatocellular carcinoma (HCC): Indirect treatment comparisons (ITC) using the RESORCE study.

A sequential therapy with sorafenib followed by regorafenib against single-line atezolizumab and bevacizumab in advanced hepatocellular carcinoma (HCC): Indirect treatment comparisons (ITC) using the RESORCE study.

Abstract Poster

Authors

Jamie Partridge

Jamie Partridge

Bayer HealthCare Pharmaceuticals, Whippany, NJ;

Jamie Partridge , David Aceituno , Noman Paracha , Howard Thom

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 537)

DOI

10.1200/JCO.2023.41.4_suppl.537

Abstract #

537

Poster Bd #

C7

Abstract Disclosures

Similar Posters

First Author: Jamie Grossman

First Author: Timothy J. Brown

First Author: David Cosgrove

First Author: M. Naomi Horiba